News – Page 539 – Endpoints News

Biogen taps digital therapeutics biotech for music-based therapy to help people with MS improve their walking

4 years ago

After last month's adcomm death knell on its ALS drug, Amylyx looks to post-hoc for saving grace

4 years ago

Illumina and Deerfield link arms to drive 'genomics-first' drug discovery

4 years ago

Big Pharma is rich. So much so, their coffers could buy more than 600 biotechs

4 years ago

Bear market slows PepGen's roll, causing DMD-focused biotech to price below range

4 years ago

SEC shines regulatory spotlight on I-Mab, Sinovac and others as more Chinese biotechs scramble to comply with new law

4 years ago

Safety risk pushes FDA to cut off J&J's Covid-19 vaccine with some limited exceptions

4 years ago

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter ...

4 years ago

PBMs in the Senate hot seat as bipartisan transparency measures may take root

4 years ago

Two Novartis sites stop manufacturing cancer therapies after quality issues

4 years ago

AstraZeneca's Ultomiris hits primary endpoint for PhIII NMOSD study

4 years ago

Are pharma marketers finally moving away from traditional TV advertising? Yes, but it’s a slow roll

4 years ago

In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports

4 years ago

J&J sues company over alleged abuse of its cost assistance program

4 years ago

FDA to create training program to inspect more mRNA vaccine manufacturing

4 years ago

Sanofi reorganizes philanthropy effort, debuts Foundation S 'think and do tank'

4 years ago

Societal nabs sole supplier role for Ritalin to Europe

4 years ago

Matica's cell & gene therapy site up and running in Texas

4 years ago

BioCryst officially gets partial clinical hold on lead candidate after halting enrollment

4 years ago

Shrinking BridgeBio confirms layoffs, details out-licensing plans for its ‘restructuring initiative’

4 years ago

Avalo Therapeutics to lay off 33% of staff amidst market struggles and penny stock status

4 years ago

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations

4 years ago

Intercept sells ex-US rights to PBC drug as it gears up for a second-chance shot at NASH

4 years ago

DCT startup looking to forge better community relationships nets a modest Series B

4 years ago

First page Previous page 536 537 538539540 541 542 Next page Last page